DBCG trial 89B comparing adjuvant CMF and ovarian ablation: Similar outcome for eligible but non-enrolled and randomized breast cancer patients

Author： Ejlertsen Bent   Jensen Maj-Britt   Mouridsen Henning   Andersen Jørn   Cold Søren   Jakobsen Erik   Kamby Claus   Sørensen Peter   Ewertz Marianne  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.47, Iss.4, 2008-01, pp. : 709-717

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Upregulation of HER-2/neu by Ovarian Ablation: Results of a Randomized Trial Comparing Leuprorelin to CMF as Adjuvant Therapy in Node-positive Breast Cancer Patients

By Lüftner D.  

Breast Cancer Research and Treatment, Vol. 80, Iss. 3, 2003-08 ,pp. : 245-255

Springer Publishing Company

Access to resources Recommend Favorite

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

By Amadori Dino   Silvestrini Rosella   Lena Mario   Boccardo Francesco   Rocca Andrea   Scarpi Emanuela   Schittulli Francesco   Brandi Mario   Maltoni Roberta   Serra Patrizia   Ponzone Riccardo   Biglia Nicoletta   Gianni Lorenzo   Tienghi Amelia   Valerio Maria   Bonginelli Paola   Amaducci Laura   Faedi Marina   Baldini Editta   Paradiso Angelo  

Breast Cancer Research and Treatment, Vol. 125, Iss. 3, 2011-02 ,pp. : 775-784

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: Indirect comparison of dose and schedule in DBCG trials 77, 82, and 89

By Ejlertsen Bent   Mouridsen Henning   Jensen Maj-Britt  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 662-671

Informa Healthcare

Access to resources Recommend Favorite

Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial

By O’Malley F.   Chia S.   Tu D.   Shepherd L.   Levine M.   Huntsman D.   Bramwell V.   Andrulis I.   Pritchard K.  

Breast Cancer Research and Treatment, Vol. 128, Iss. 2, 2011-07 ,pp. : 401-409

Springer Publishing Company

Access to resources Recommend Favorite

Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients - a prospective, comparative, non-randomised study

By Fiets W.E.   van Helvoirt R.P.   Nortier J.W.R.   van der Tweel I.   Struikmans H.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1081-1088

Elsevier

Access to resources Recommend Favorite